Andrea Mangano

Dr. Andrea Mangano


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2010 in Retrovirology
Verified
Journal Article
Open access
PDF file
GBGonzalo Bello
Gonzalo Bello
PAPaula C Aulicino
Paula C Aulicino
DRDora Ruchansky
Dora Ruchansky
MGMonick Lindenmeyer Guimarães
Monick Lindenmeyer Guimarães
CLCecilio Lopez-Galindez
Cecilio Lopez-Galindez
MMMariza Gonçalves Morgado
Mariza Gonçalves Morgado
Although HIV-1 CRF12_BF and CRF38_BF are two epidemiologically important recombinant lineages circulating in Argentina and Uruguay, little is known about their population dynamics.

22 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMaría Verónica Pineda
María Verónica Pineda
MBMaría Belen Bouzas
María Belen Bouzas
MRMirta Remesar
Mirta Remesar
AFAriel Fridman
Ariel Fridman
CRCarlos Remondegui
Carlos Remondegui
AMAndrea Mangano
Andrea Mangano
HTLV-1 proviral load (pVL) in peripheral blood mononuclear cell (PBMCs) is proposed as a marker of disease progression but its role still remains controversial. The aim of this study was to evaluate the levels of HTLV-1 pVL in symptomatic patients and asymptomatic HTLV-1 carriers. In this cross-sectional study the pVL was measured by Real Time PCR in 102 asymptomatic carriers and 22 symptomatic patients (5ATLL, 15 TSP and 2 uveitis). We observed that the HTLV-1 pVL was significantly higher in symptomatic patients (median = 4.99 log10 HTLV-1 copies /106 PBMCs) compared to asymptomatic HTLV-1 carriers (median = 4.38 log10 HTLV-1 copies /106 PBMCs; p = 0.0030). A wide variation on the HTLV-1 pVL levels among asymptomatic HTLV-1 carriers was observed with some pVL as high as those observed in symptomatic patients. The asymptomatic HTLV-1 carriers were divided according to the place of birth and the highest levels of pVL were detected among patients from endemics areas from the North of Argentina. Our results reinforce the usefulness of the proviral load would be a prognostic marker of HTLV-1 disease progression. Moreover, host, viral or socio-environmental factors cannot be excluded as determinant of high proviral load.

1 January 2015 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
LGLuis Pablo Gravina
Luis Pablo Gravina
CCCarolina Crespo
Carolina Crespo
HGHilda Giugno
Hilda Giugno
LSLuisa Sen
Luisa Sen
LCLilien Chertkoff
Lilien Chertkoff
CCClaudio Castaños
Claudio Castaños

23 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMatías Moragas
Matías Moragas
MDMaximiliano Distefano
Maximiliano Distefano
DMDebora Mecikovsky
Debora Mecikovsky
SCSolange Arazi Caillaud
Solange Arazi Caillaud
CCCarolina Cernadas
Carolina Cernadas
AMAndrea Mangano
Andrea Mangano
Determine the decay rate of HIV-1 DNA reservoir in vertically infected children during sustained viral suppression (VS) and how it is affected by the age at VS. This study included 37 HIV-1 vertically infected children on suppressive antiretroviral therapy for at least 4 years. Children were grouped according to the age of antiretroviral therapy initiation (≤0.5 or >0.5 yrs) and to the age at VS (≤1.5, between >1.5 and 4, and >4 years). Decay of cell-associated HIV-1 DNA (CA-HIV-DNA) level and 2-long terminal repeats (2-LTR) circles frequency were analyzed over 4 years of viral suppression using piecewise linear mixed-effects model with two splines and logistic regression, respectively. CA-HIV-DNA in peripheral blood mononuclear cells had a significant decay during the first two years of VS [-0.26 (95% CI: -0.43, -0.09) log10 copies per one million cells (cpm)/year], and subsequently reached a plateau [-0.06 (95% CI: -0.15, 0.55) log10 cpm/year]. The initial decay was higher in children who achieved VS by 1.5 years of age compared to those who achieved VS between >1.5 and 4 years and those after 4 years of age: -0.51 (95% CI:-0.94, -0.07), -0.35 (95% CI:-0.83, 0.14), and -0.21 (95% CI:-0.39, -0.02) log10cpm PBMC/year, respectively. The 2-LTR circles frequency decayed significantly, from 82.9% at pre-VS to 37.5% and 28.1% at 2 and 4 years of VS, respectively (P = .0009). These data highlight that achieving VS during the first 18 months of life limit the establishment of HIV-1 reservoirs, reinforcing the clinical benefit of very early effective therapy in children.

29 April 2015 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
MMM. Moragas
M. Moragas
WBW. H. Belloso
W. H. Belloso
MBM. S. Baquedano
M. S. Baquedano
MGM. I. Gutierrez
M. I. Gutierrez
EBE. Bissio
E. Bissio
AMAndrea Mangano
Andrea Mangano